Campbell & CO Investment Adviser LLC Invests $2.31 Million in United Therapeutics Corporation $UTHR

Key Points

• Campbell & CO Investment Adviser LLC acquired a new stake in United Therapeutics Corporation, purchasing 7,502 shares valued at approximately $2.31 million in Q1.
• Insider selling activity included Director Richard Giltner and Nilda Mesa, who sold a combined total of 3,681 shares worth over $1 million, indicating a decrease in their ownership percentages.
• United Therapeutics reported Q2 earnings with an EPS of $6.41, missing the estimate of $6.80, while revenue increased by 11.7% year-over-year.

Campbell & CO Investment Adviser LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 7,502 shares of the biotechnology company's stock, valued at approximately $2,313,000.

A number of other institutional investors have also made changes to their positions in the stock. Quantitative Investment Management LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at approximately $944,000. SVB Wealth LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at approximately $32,000. Cadence Bank raised its stake in shares of United Therapeutics by 1.2% in the 1st quarter. Cadence Bank now owns 3,963 shares of the biotechnology company's stock valued at $1,222,000 after acquiring an additional 47 shares in the last quarter. Allstate Corp raised its stake in shares of United Therapeutics by 64.1% in the 1st quarter. Allstate Corp now owns 1,930 shares of the biotechnology company's stock valued at $595,000 after acquiring an additional 754 shares in the last quarter. Finally, Integrated Investment Consultants LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at approximately $266,000. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on UTHR shares. Bank of America cut their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Wells Fargo & Company cut their price objective on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Morgan Stanley dropped their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Finally, JPMorgan Chase & Co. dropped their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $382.00.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the transaction, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock worth $24,537,839 in the last quarter. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $2.48 during trading on Friday, hitting $304.76. 418,774 shares of the stock were exchanged, compared to its average volume of 795,594. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The company has a market capitalization of $13.75 billion, a price-to-earnings ratio of 11.90, a price-to-earnings-growth ratio of 4.62 and a beta of 0.57. The company's fifty day simple moving average is $298.66 and its 200-day simple moving average is $305.68.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics's revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period in the previous year, the business posted $5.85 EPS. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.